Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07400588
PHASE2

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).

Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight

Key Details

Gender

All

Age Range

18 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2025-12-01

Completion Date

2026-11

Last Updated

2026-02-10

Healthy Volunteers

No

Interventions

DRUG

Aleniglipron

Drug aleniglipron administered orally

DRUG

Placebo

Drug placebo administered orally

Locations (17)

Research Site

Anniston, Alabama, United States

Research Site

Lake Forest, California, United States

Research Site

Lomita, California, United States

Research Site

Hazelwood, Missouri, United States

Research Site

Columbus, Ohio, United States

Research Site

Moncks Corner, South Carolina, United States

Research Site

Chattanooga, Tennessee, United States

Research Site

Knoxville, Tennessee, United States

Research Site

Austin, Texas, United States

Research Site

Austin, Texas, United States

Research Site

DeSoto, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Mesquite, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

Tomball, Texas, United States